The long-term objective of these studies is to develop an effective therapy for dominantly inherited, late onset, neurodegenerative diseases caused by expansions in CAG repeats. The CAG/polyglutamine expansion has been found to form the molecular basis for at least seven neurodegenerative diseases. These include Huntington's disease (HD), spinal and bulbar muscular atrophy (SBMA, Kennedy's disease), Machado-Joseph disease (MJD or SCA-3), dentatorubropallidoluysian atrophy (DRPLA), and spinocerebellar ataxias types 1, 2, and 6 (SCA-1, SCA-2, and SCA-6). In all cases, there is selective death of neurons in different brain regions and the clinical symptoms correlate with the affected regions. The function of most of these disease causing proteins is unknown and the proteins appear to be functionally unrelated except for the polyglutamine tract. Expansion of the glutamine repeat in all these proteins appears to confer upon the disease protein a toxic gain-of-function that is selectively deleterious to neurons. The goal of the proposed research is to define a common relationship between these seven disease-associated gene products. We will test our hypothesis that the seven polyglutamine containing proteins are pro-apoptotic, and that the pro-apoptotic phenotype is dependent upon cleavage of these proteins by cell death executioners, the caspases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS040251-03
Application #
6394473
Study Section
Neurology B Subcommittee 2 (NEUB)
Program Officer
Gwinn, Katrina
Project Start
1999-09-28
Project End
2003-08-31
Budget Start
2001-09-01
Budget End
2003-08-31
Support Year
3
Fiscal Year
2001
Total Cost
$322,747
Indirect Cost
Name
Buck Institute for Age Research
Department
Type
DUNS #
800772162
City
Novato
State
CA
Country
United States
Zip Code
94945
Tracy, Tara E; Sohn, Peter Dongmin; Minami, S Sakura et al. (2016) Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss. Neuron 90:245-60
Min, Sang-Won; Chen, Xu; Tracy, Tara E et al. (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21:1154-62
Guyenet, Stephan J; Mookerjee, Shona S; Lin, Amy et al. (2015) Proteolytic cleavage of ataxin-7 promotes SCA7 retinal degeneration and neurological dysfunction. Hum Mol Genet 24:3908-17
Duncan, Carlotta E; An, Mahru C; Papanikolaou, Theodora et al. (2013) Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model. Mol Neurodegener 8:42
Miller, John P; Yates, Bridget E; Al-Ramahi, Ismael et al. (2012) A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease. PLoS Genet 8:e1003042
Gafni, Juliette; Papanikolaou, Theodora; Degiacomo, Francesco et al. (2012) Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J Neurosci 32:7454-65
Zhang, Ningzhe; Li, Bensheng; Al-Ramahi, Ismael et al. (2012) Inhibition of lipid signaling enzyme diacylglycerol kinase epsilon attenuates mutant huntingtin toxicity. J Biol Chem 287:21204-13
Cong, Xin; Held, Jason M; DeGiacomo, Francesco et al. (2011) Mass spectrometric identification of novel lysine acetylation sites in huntingtin. Mol Cell Proteomics 10:M111.009829
Leyva, Melissa J; Degiacomo, Francesco; Kaltenbach, Linda S et al. (2010) Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models. Chem Biol 17:1189-200
Landles, Christian; Sathasivam, Kirupa; Weiss, Andreas et al. (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem 285:8808-23

Showing the most recent 10 out of 33 publications